EP3785711 - UTILIZATION OF CILASTATIN IN INHIBITING RENAL DISORDER INDUCED BY IOVERSOL,IOMEPROL OR IODIXANOL [Right-click to bookmark this link] | |||
Former [2021/09] | UTILIZATION OF CILASTATIN IN INHIBITING RENAL DISORDER | ||
[2022/22] | Status | No opposition filed within time limit Status updated on 15.09.2023 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 07.10.2022 | ||
Former | Grant of patent is intended Status updated on 02.06.2022 | ||
Former | Examination is in progress Status updated on 05.11.2021 | ||
Former | Request for examination was made Status updated on 29.01.2021 | ||
Former | The international publication has been made Status updated on 02.11.2019 | Most recent event Tooltip | 24.05.2024 | Lapse of the patent in a contracting state New state(s): IT | published on 26.06.2024 [2024/26] | Applicant(s) | For all designated states Niigata University 8050, Ikarashi Ninocho Nishi-ku Niigata-shi Niigata 950-2181 / JP | For all designated states Denka Company Limited 1-1, Nihonbashi-Muromachi 2-chome Chuo-ku Tokyo 103-8338 / JP | [2021/09] | Inventor(s) | 01 /
SAITO, Akihiko c/o Graduate School of Medical and Dental Science Medicine), Niigata University, 1-757 Asahimachi- dori, Chuo-ku Niigata-shi, Niigata 951-8510 / JP | 02 /
GOTO, Sawako c/o Graduate School of Medical and Dental Science Medicine), Niigata University, 1-757 Asahimachi- dori, Chuo-ku Niigata-shi, Niigata 951-8510 / JP | 03 /
HIRAYAMA, Yoshiaki c/o Denka Seiken Co.,Ltd., 1-1, Nihonbashi- Muromachi 2-chome, Chuo-ku Tokyo 103-8338 / JP | 04 /
SEKINE, Sakari c/o Denka Company Limited, 1-1, Nihonbashi- Muromachi 2-chome, Chuo-ku Tokyo 103-8338 / JP | [2021/09] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE | [2021/09] | Application number, filing date | 19794059.6 | 26.04.2019 | [2021/09] | WO2019JP17963 | Priority number, date | JP20180087294 | 27.04.2018 Original published format: JP 2018087294 | JP20180225035 | 30.11.2018 Original published format: JP 2018225035 | [2021/09] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019208777 | Date: | 31.10.2019 | Language: | JA | [2019/44] | Type: | A1 Application with search report | No.: | EP3785711 | Date: | 03.03.2021 | Language: | EN | [2021/09] | Type: | B1 Patent specification | No.: | EP3785711 | Date: | 09.11.2022 | Language: | EN | [2022/45] | Search report(s) | International search report - published on: | JP | 31.10.2019 | (Supplementary) European search report - dispatched on: | EP | 03.05.2021 | Classification | IPC: | A61K31/198, A61P13/12, A61K49/04 | [2021/09] | CPC: |
A61K9/0019 (EP,US);
A61K31/198 (EP,US);
A61K49/04 (EP,US);
A61P13/12 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/09] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | VERWENDUNG VON CILASTATIN ZUR HEMMUNG VON DURCH IOVERSOL,IOMEPROL ODER IODIXANOL VERURSACHTEN NIERENERKRANKUNGEN | [2022/22] | English: | UTILIZATION OF CILASTATIN IN INHIBITING RENAL DISORDER INDUCED BY IOVERSOL,IOMEPROL OR IODIXANOL | [2022/22] | French: | UTILISATION DE LA CILASTATINE DANS L'INHIBITION D'UN TROUBLE RÉNAL PROVOQUÉ PAR IOVERSOL,IOMEPROL OU IODIXANOL | [2022/22] |
Former [2021/09] | VERWENDUNG VON CILASTATIN ZUR HEMMUNG VON NIERENERKRANKUNGEN | ||
Former [2021/09] | UTILIZATION OF CILASTATIN IN INHIBITING RENAL DISORDER | ||
Former [2021/09] | UTILISATION DE LA CILASTATINE DANS L'INHIBITION D'UN TROUBLE RÉNAL | Entry into regional phase | 28.10.2020 | Translation filed | 26.11.2020 | National basic fee paid | 26.11.2020 | Search fee paid | 26.11.2020 | Designation fee(s) paid | 26.11.2020 | Examination fee paid | Examination procedure | 26.11.2020 | Examination requested [2021/09] | 17.08.2021 | Amendment by applicant (claims and/or description) | 09.11.2021 | Despatch of a communication from the examining division (Time limit: M04) | 07.03.2022 | Reply to a communication from the examining division | 03.06.2022 | Communication of intention to grant the patent | 05.10.2022 | Fee for grant paid | 05.10.2022 | Fee for publishing/printing paid | 05.10.2022 | Receipt of the translation of the claim(s) | Opposition(s) | 10.08.2023 | No opposition filed within time limit [2023/42] | Fees paid | Renewal fee | 15.12.2020 | Renewal fee patent year 03 | 29.03.2022 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 09.11.2022 | AT | 09.11.2022 | CZ | 09.11.2022 | DK | 09.11.2022 | EE | 09.11.2022 | ES | 09.11.2022 | FI | 09.11.2022 | HR | 09.11.2022 | IT | 09.11.2022 | LT | 09.11.2022 | LV | 09.11.2022 | MC | 09.11.2022 | NL | 09.11.2022 | PL | 09.11.2022 | RO | 09.11.2022 | RS | 09.11.2022 | SE | 09.11.2022 | SI | 09.11.2022 | SK | 09.11.2022 | SM | 09.11.2022 | NO | 09.02.2023 | GR | 10.02.2023 | IS | 09.03.2023 | PT | 09.03.2023 | IE | 26.04.2023 | LU | 26.04.2023 | BE | 30.04.2023 | CH | 30.04.2023 | LI | 30.04.2023 | [2024/26] |
Former [2024/21] | AL | 09.11.2022 | |
AT | 09.11.2022 | ||
CZ | 09.11.2022 | ||
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
MC | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RO | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SI | 09.11.2022 | ||
SK | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
IE | 26.04.2023 | ||
LU | 26.04.2023 | ||
BE | 30.04.2023 | ||
CH | 30.04.2023 | ||
LI | 30.04.2023 | ||
Former [2024/12] | AL | 09.11.2022 | |
AT | 09.11.2022 | ||
CZ | 09.11.2022 | ||
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
MC | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RO | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SI | 09.11.2022 | ||
SK | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
LU | 26.04.2023 | ||
BE | 30.04.2023 | ||
CH | 30.04.2023 | ||
LI | 30.04.2023 | ||
Former [2024/09] | AL | 09.11.2022 | |
AT | 09.11.2022 | ||
CZ | 09.11.2022 | ||
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
MC | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RO | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SI | 09.11.2022 | ||
SK | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
LU | 26.04.2023 | ||
CH | 30.04.2023 | ||
LI | 30.04.2023 | ||
Former [2024/08] | AL | 09.11.2022 | |
AT | 09.11.2022 | ||
CZ | 09.11.2022 | ||
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
MC | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RO | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SI | 09.11.2022 | ||
SK | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
LU | 26.04.2023 | ||
Former [2024/04] | AL | 09.11.2022 | |
AT | 09.11.2022 | ||
CZ | 09.11.2022 | ||
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RO | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SI | 09.11.2022 | ||
SK | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
LU | 26.04.2023 | ||
Former [2023/51] | AL | 09.11.2022 | |
AT | 09.11.2022 | ||
CZ | 09.11.2022 | ||
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RO | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SI | 09.11.2022 | ||
SK | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/38] | AL | 09.11.2022 | |
AT | 09.11.2022 | ||
CZ | 09.11.2022 | ||
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RO | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SK | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/37] | AL | 09.11.2022 | |
AT | 09.11.2022 | ||
CZ | 09.11.2022 | ||
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RO | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/35] | AT | 09.11.2022 | |
CZ | 09.11.2022 | ||
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RO | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/34] | AT | 09.11.2022 | |
DK | 09.11.2022 | ||
EE | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/33] | AT | 09.11.2022 | |
DK | 09.11.2022 | ||
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
SM | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/29] | AT | 09.11.2022 | |
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
NL | 09.11.2022 | ||
PL | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/25] | AT | 09.11.2022 | |
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
HR | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
PL | 09.11.2022 | ||
RS | 09.11.2022 | ||
SE | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
IS | 09.03.2023 | ||
PT | 09.03.2023 | ||
Former [2023/23] | AT | 09.11.2022 | |
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
LT | 09.11.2022 | ||
LV | 09.11.2022 | ||
SE | 09.11.2022 | ||
NO | 09.02.2023 | ||
GR | 10.02.2023 | ||
PT | 09.03.2023 | ||
Former [2023/22] | AT | 09.11.2022 | |
ES | 09.11.2022 | ||
FI | 09.11.2022 | ||
LT | 09.11.2022 | ||
SE | 09.11.2022 | ||
NO | 09.02.2023 | ||
PT | 09.03.2023 | ||
Former [2023/20] | LT | 09.11.2022 | |
NO | 09.02.2023 | Documents cited: | Search | [A] - ON BEHALF OF THE CONTRAST MEDIA SAFETY COMMITTEE OF EUROPEAN SOCIETY OF UROGENITAL RADIOLOGY (ESUR) ET AL, "Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines", EUROPEAN RADIOLOGY, SPRINGER, BERLIN, DE, (20110825), vol. 21, no. 12, doi:10.1007/S00330-011-2225-0, ISSN 1432-1084, pages 2527 - 2541, XP019978116 [A] 1-3 * page 2531 - page 2534 * DOI: http://dx.doi.org/10.1007/s00330-011-2225-0 | [A] - YOSHIHISA HORI ET AL, "Megalin Blockade with Cilastatin Suppresses Drug-Induced Nephrotoxicity", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, (20170601), vol. 28, no. 6, doi:YOSHIHISA HORI, NOBUMASA AOKI,SHOJI KUWAHARA, ISSN 1046-6673, pages 1783 - 1791, XP009194737 [A] 1-3 * abstract * DOI: http://dx.doi.org/Yoshihisa Hori, Nobumasa Aoki,Shoji Kuwahara | International search | [A]US2011165264 (TEJEDOR JORGE ALBERTO [ES], et al) [A] 1-3* , claims, examples *; | [A]WO2015111666 (AJINOMOTO KK [JP], et al) [A] 1-3 * , claims, examples (Family: none) *; | [A]KR20170086851 (IM DAI SIG [KR]) [A] 1-3 * , claims, paragraphs [0030]-[0031], [0049], example 3, fig. 3 (Family: none) * | by applicant | JP2003261459 | WO2015111666 | US9216185 | - Guidelines on the Use of Iodinated Contrast Media in Patients with Kidney Disease 2012, JSN, JRS and JCS Joint Working Group, pages 50 - 79 | - MARZOLO et al., Biological Research, (20110000), vol. 44, pages 89 - 105 | - CHRISTENSEN et al., Nature Reviews Molecular Cell Biology, (20020000), vol. 3, pages 258 - 268 | - OYAMA et al., Laboratory Investigation, (20050000), vol. 85, pages 522 - 531 | - NORDBY et al., Scanning Microsc, (19900000), vol. 4, pages 651 - 666 | - TANAKA et al., BMJ Open, (20140000), vol. 4, page e004407 | - MORIYAMA et al., Am JRespir Crit Care Med, (20070000), vol. 176, pages 70 - 77 | - ZHANG et al., Kidney Int, (20080000), vol. 73, pages 608 - 614 | - ORLANDO et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, pages 6698 - 6702 | - DE et al., Diabetes, (20170000), vol. 66, pages 1391 - 1401 |